Cancer victims who suffer from myelofibrosis can live for many years after diagnosis without presenting symptoms, provided that they are in a good prognosis group and the disease is managed properly, according to MPN Research Foundation. Myelofibrosis is a chronic blood cancer.
Life expectancy varies greatly by the patient's prognosis, which is most significantly affected by age, white blood cell count, anemia, transfusion dependence and the number of "blasts," or immature blood cells, in the blood, explains MPN Research Foundation. Myelofibrosis is most commonly diagnosed in patients between the ages of 60 and 70. In rare cases, it can transform into acute myeloid leukemia, a quickly progressing blood and marrow cancer which can negatively impact life expectancy.